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S U M M A R Y
Background: Pneumococcal colonization of the nasopharynx is especially common in young children and
is a pre-requisite for pneumococcal disease. Those with immunosuppression, such as HIV, are at higher
risk of colonization and disease, especially at older ages. Currently, vaccination schedules are only
offered to children under 6 months of age, despite the large impact of pneumococcal disease in older
unvaccinated children with HIV. We conducted a study to assess the prevalence of, and risk factors for,
pneumococcal carriage in HIV-positive children aged <15 years.
Methods: We collected a single nasopharyngeal swab from 142 HIV-infected children aged 1–14 years
over a 2-month period. To detect carriage of pneumococcus, these samples were cultured and serotyped;
PCR was performed on negative samples. We also collected epidemiological data via survey and medical
records.
Results: The overall carriage rate was 81% and was at least 76% in those aged 5–14 years. The 7-, 10-, and
13-valent pneumococcal vaccines would cover 37%, 37%, and 49% of children with carriage, respectively.
In the multivariate analysis, we identiﬁed increase in weight since last visit (p = 0.028) and the existence
of care-givers who had respiratory symptoms in the past week (p = 0.022) as risk factors for carriage.
Weight gain was also signiﬁcantly associated with antiretroviral use (p = 0.002).
Conclusions: These data illuminate the little known area of pneumococcal carriage in older HIV-infected
children as well as ﬁnding novel risk factors for pneumococcal carriage, namely the association with
household members who have respiratory symptoms and with an increase in the child’s weight prior to
swabbing. Weight gain may be due to an increase in health enabling more mobility and increasing the risk
of acquiring carriage. The carriage rate observed (81%) is one of the highest recorded. Further research
should address whether vaccination can prevent the acquisition of carriage and so protect against disease.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pneumoniae is a Gram-positive bacterium with
over 90 serotypes identiﬁed. Pneumococci colonize the* Corresponding author. Tel.: +61 2 9845 1415; fax: +61 2 9845 1418.
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http://dx.doi.org/10.1016/j.ijid.2012.05.1037nasopharynx asymptomatically, and usually transiently, for
weeks or up to months.1 Carriage is a prerequisite for invasive
disease, such as pneumonia, meningitis, or septicemia to
develop.2 The World Health Organization (WHO) reports that
invasive pneumococcal disease causes up to one million
childhood deaths per year.3,4
The association between S. pneumoniae and pneumonia was
described in 1883, while the association of pneumococcal capsularses. Published by Elsevier Ltd. All rights reserved.
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described in 1915.5
Bacterial disease is a leading cause of mortality and morbidity
in children in the developing world,4,6,7 especially those with
HIV.8,9 HIV-positive children aged <2 years have about a 40 times
greater risk of invasive pneumococcal disease compared to healthy
children; these infections are more likely to be fatal,9,10 and
importantly the incidence does not decline with age as in healthy
children.9–12
Mortality and morbidity in children with HIV may be reduced
by vaccination against pneumococcal disease.8 Antiretroviral
therapy also reduces disease, but long-term delivery is logistically
challenging. It was recently estimated that up to 90% of Tanzanians
in need of antiretrovirals (ARVs) were not receiving them.13 A
pneumococcal vaccination program, on the other hand, is
relatively cheaper, and pneumococcal vaccines are both well
tolerated and immunogenic in HIV-infected infants.13 It has been
shown that pneumococcal vaccination has prevented death,
invasive disease, and pneumonia in African infants with and
without HIV infection.8,14,15
Research has concentrated on looking at the effectiveness of the
vaccine in infants vaccinated when only a few months old.
Vaccination has already been shown to be immunogenic in older
children.15 Thus, before a policy decision is implemented regarding
immunization of older children (>1 year) living with HIV (2.3
million16), it is important to better examine the prevalence of, and
risk factors for, pneumococcal carriage in this population.
This paper aimed to examine the prevalence of, and risk factors
for, S. pneumoniae carriage in HIV-positive children, to identify the
serotypes circulating in this population (without vaccine pressure),
and to estimate the theoretical coverage offered by different
conjugate vaccines. Identifying risk factors for colonization can
inform methods to better control transmission and ultimately
reduce the incidence of invasive disease. Pneumococcal conjugate
vaccine (PCV) has been shown to reduce vaccine-type carriage,
although this may require higher serum antibody concentrations
than is needed to prevent pneumococcal disease.17
2. Methods
The study was conducted at The Diana Centre, Teule Hospital in
Muheza, a rural town in Tanzania, which has a leading HIV
treatment clinic. The Centre receives funding from the govern-
ment, plus private and non-governmental organization (NGO)
sources. It is an outpatient-based service that both educates and
treats people with HIV.Table 1
Comparison (univariate analyses and ﬁnal model of multivariate analysis) of characterist
Characteristic Car
Univariate analysis
Age, years, mean (SD) 6.3
Female, n (%) 57/
Number of household members diagnosed with HIV, mean (SD) 0.8
Children exposed to passive smoking in the house, n (%) 36/
Children sleeping in a room where cooking is done, n (%) 53/
Children currently attending school, n (%) 52/
Children with a recent (in the past week) respiratory infection, n (%) 82/
Latest CD4 count, mean (median) 752
Signs of malnutrition, n (%) 12/
Gaining weight (compared with last outpatient visit), n (%) 54/
Antiretrovirals taken, n (%) 61/
Number of household members, mean (SD) 5.0
Children whose care-giver had respiratory symptoms in past week, n (%) 50/
Final model of multivariate analysis
Gaining weight (compared with last outpatient visit), n (%) 54/
Children whose care-giver had respiratory symptoms in past week, n (%) 50/
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation.2.1. Recruitment
Inclusion criteria for children of The Diana Centre required all
three of the following: informed consent from the primary care-
giver (i.e., usually the mother, but in a small minority from a
guardian, usually an aunt), HIV-positive, and age between 1 and 14
years. Exclusion criteria were: refusal to participate, presence of
contraindications to a nasopharyngeal swab (such as thrombocy-
topenia), presence of severe disease (any condition requiring
immediate medical treatment as determined by medical personnel
or researchers), or previous receipt of pneumococcal vaccination.
2.2. Data and swab collection
A questionnaire was administered to care-givers at recruitment
which collected epidemiological data including recent respiratory
symptoms in the household and previous HIV treatment. Health
data including CD4+ count were obtained from medical records.
Detailed data on risk factors were collected from children, primary
care-givers, and other household members (Table 1).
Swabs (Medical Wire and Equipment, UK) were collected and
processed according to the WHO working group standard methods
for detecting upper respiratory carriage of S. pneumoniae.18,19 The
serotype of isolates from culture-positive specimens was deter-
mined by the Quellung reaction, using antisera supplied by the
Statens Serum Institut (Copenhagen, Denmark).
Culture-negative samples were tested by lytA PCR (speciﬁc for S.
pneumoniae identiﬁcation) using a TaqMan probe and primers as
described by McAvin et al.,20 except that the result was read by
spectroﬂuorometry and interpreted as described by Poddar and Le.21
Brieﬂy, a 25-ml PCR reaction containing 1.5 mM MgCl2, 200 mM
dNTPs, 200 nM of each primer, 120 nM probe, 1.23 U HotStarTaq
DNA polymerase, and 10 ml of total nucleic acid, yielded a 101-bp
product. The PCR cycling conditions were: initial denaturation at
95 8C for 15 min, followed by 45 cycles at 96 8C for 10 s, 63 8C for
1 min, and a ﬁnal extension step of 72 8C for 2 min. The end-point
results were analyzed by calculating the post- to pre-read ratio.
Samples with ratios of 2.78 were reported as positive and
conﬁrmed using gel electrophoresis on a 2% gel, at 200 V for
40 min. Samples with ratios of 1.21 were reported as negative. The
limit of detection of the assay was 6 colony-forming units (CFU)/ml.
2.3. Pneumococcal serotype identiﬁcation
All samples in which S. pneumoniae was detected by PCR were
examined by multiplex PCR reverse line assay (mPCR/RLB) toics between HIV-infected children who were pneumococcal carriers or non-carriers
riers (n = 115) Non-carriers (n = 27) OR (95% CI) p-Value
9 (3.18) 7.54 (3.18) Not applicable 0.100
109 (52%) 14/26 (54%) 0.94 (0.40–2.22) 0.887
9 (0.82) 0.50 (0.72) Not applicable 0.053
110 (33%) 7/25 (28%) 1.25 (0.48–3.27) 0.647
110 (48%) 13/26 (50%) 0.93 (0.40–2.19) 0.868
107 (49%) 17/26 (65%) 0.50 (0.21–1.22) 0.124
109 (75%) 18/26 (69%) 1.35 (0.53–3.45) 0.531
 (540) 733 (441) Not applicable 0.879
109 (11%) 4/26 (15%) 0.68 (0.20–2.31) 0.535
83 (65%) 8/22 (36%) 3.26 (1.22–8.67) 0.015
95 (64%) 11/26 (42%) 2.45 (1.01–5.92) 0.044
2 (1.85) 5.19 (2.12) Not applicable 0.680
110 (45%) 5/25 (20%) 3.33 (1.17–9.52) 0.019
83 (65%) 8/22 (36%) 3.62 (1.21–10.89) 0.028
110 (45%) 5/25 (20%) 2.97 (1.12–7.86) 0.022
From September 30 to December 11, 2008, 
160 children and their families were 
approached 
Enrolled 145 children 
15 Carers declined to 
participate or did not 
want to be swabbed 
3 children dropped 
out from the study 
142 children included in the 
analysis 
Figure 1. Flow of study participants.
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serotypes, as previously described.22,23 If serogroup 6 was
identiﬁed, serotype-speciﬁc PCRs targeting wciP, to distinguish
serotypes 6A and 6C from 6B, and the wciN single nucleotide
polymorphism (SNP), which distinguishes serotype 6A from 6C,24
were performed. Samples that gave no signals in mPCR/RLB (n =
33) (result recorded as ‘below detection level’ (BDL)) and those in
which only the SP-positive control probes targeting ply or lytA
produced signals (‘non-typeable’ (NT)) were further tested, if
sufﬁcient DNA remained, by PCR and sequencing of the cpsA–B
region of the capsular polysaccharide synthesis (cps) gene cluster,
as previously described and validated.25
2.4. Statistical analysis
To assess the association between pneumococcal carriage and
each risk factor, the Chi-square test was employed for univariate
analysis, which provided odds ratio (OR) and 95% conﬁdence
intervals (CIs). Multiple logistic regression was applied using risk
factors with p < 0.25 on univariate analysis to produce the ﬁnal
model containing only signiﬁcant variables. All the statistical data
analyses were performed using SPSS version 19 (IBM, USA).
3. Results
Between September 30 and December 11, 2008, 160 children
and their families were approached; 148 initially agreed to take
part but six children refused to be swabbed (Figure 1). Pneumo-
cocci were isolated (or detected by PCR) from the nasopharyngeal
swab of 115/142 (81%) children: 93 by culture and 22 by PCR.
The age was recorded for 138 of the 142 children; three of the
four children of uncertain age had positive swabs. The age-speciﬁc
carriage prevalences were: 88% in those aged 1–4 years (46/52),
77% in those aged 5–9 years (47/61), and 76% in those aged 10–14
years (19/25, p = 0.13). All swabs yielded a single pneumococcal
serotype with the exception of one from a 2.5-year-old child who
was colonized with two serotypes (19A and 9 V).
We detected 31 serotypes among the 115 positive samples; 13
positive samples were BDL. We assessed the frequency of each
serotype (Figure 2). The most common were 19F (11%) and 11A
(9%). The 7-, 10-, and 13-valent vaccines covered 43/115 (37%), 43/
115 (37%), and 56/115 (49%) of the colonizing serotypes,
respectively (Table 2).
We compared several characteristics between the carriers and
non-carriers (Table 1). On multivariate analysis, we found two
factors associated with the increased risk of an HIV-infected child
being a carrier: weight gain in the child since the last visit to the
centre (p = 0.028) and the care-giver having a respiratory infectionFigure 2. Frequency of pneumococcal serotypes isolated from nasopharyin the past week (p = 0.022). We found no differences in carriage
rates by age, school attendance, number of other people with HIV
in the household, or recent health and treatment of the child (i.e.,
presence of nasal mucus, use of ARVs, and CD4+ count). For
example, of 130 children with complete data on respiratory
symptoms, 58 had one or more symptoms (47 were carriers, 81%),
while 72 had no symptoms (59 carriers, 82%) (Table 1).
There was however a signiﬁcant association between ARV use
and weight gain (p = 0.002). However, weight gain was not
associated with the child being on ARV medication, comparing
more than 1 year treatment with less than a year.
4. Discussion
As carriage is a prerequisite for invasive disease, being able to
moderate risk factors for carriage may assist in controlling disease.
Of the variables we examined, we found two signiﬁcant predictive
risk factors: carriage was more likely if the child had gained weight
since their last visit to the clinic and if the care-giver had had a
respiratory infection in the past week.
Weight gain is probably associated with the children being
healthier, therefore more mobile and more likely to mix with other
children and adults, thus increasing the chance of transmission by
contact. There are data that support the horizontal transmission of
carriage within families, speciﬁcally between siblings.26 Howeverngeal swabs from HIV-infected children (NT = no serotype isolated).
Table 2
Serotypes carried and proportion covered by vaccines
Serotypes n 7v 10v 13v
3 7 7
4 1 1 1 1
6A 5 5
6B 7 7 7 7
7C 2
9V 6 6 6 6
13 2
14 7 7 7 7
10A 2
11A 10
12F 1
15A 3
15B 1
15C 4
16F 3
17F 1
18C 2 2 2 2
19A 1 1
19V 1
19B 1
19F 13 13 13 13
20 3
21 2
22A 1
23A 1
23B 1
23F 7 7 7 7
25A 1
34 2
35A 1
35B 3
Negative 27
Below detection level 13
Total 142 43 43 56
Denominator is 115 carriers 37% 37% 49%
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unvaccinated contacts is controversial. A study by Cheung et al.27
showed that in areas with high carriage rates, vaccination of a child
using 9-valent PCV may not provide herd immunity to siblings,
suggesting they are acquiring carriage in the community. Cheung’s
ﬁnding, however, was counter to the results of a household
carriage study by Millar et al.,28 which demonstrated an indirect
protection against vaccine-type pneumococcal carriage in the
unvaccinated household members living with a 7-valent PCV
vaccinee.
Our study showed that weight gain had a signiﬁcant association
with pneumococcal carriage, although we were not able to record
the exact weight change of subjects at each study visit. Thus, we
suggest that future studies should endeavor to increase granularity
on the measurement of recent weight change.
There is evidence supporting community transmission such as
in day-care centers. Studies of childcare transmission show
attendance is associated with greater pneumococcal carriage29–
31 and disease.32 This may have a threshold effect; a study by
Pebody et al.33 only found an association when the child attended
for more than 20 h a week.
Attending for treatment of disease may also help explain why
weight gain is associated with greater carriage. Although we found
no statistically signiﬁcant association between ARV use and
carriage, we did ﬁnd an association between ARV use and increase
in weight (p = 0.003). Carriage was not associated with duration of
ARV use (comparing treatment for <1 year vs. 1 year). ARV use
may also be associated with more effective parenting or better
access to medical care. Children may acquire carriage at the same
time they are being treated (in a crowded clinic).
The signiﬁcant association between carriage in a child and a
household member who has recently had symptoms of an upperrespiratory tract infection (URTI) may be explained by the child
passing an infection to the care-giver or by carriage acquisition in
the child from a coughing household member. In the wake of the
impressive herd effect seen after pneumococcal conjugate
vaccination was introduced in the USA,34–36 there were studies
associating carriage in children with invasive disease in care-
givers.37 As far as we can tell, there are no data on the association
between respiratory illness in adult household members and
pneumococcal carriage (or disease) in children. Another explana-
tion could be that the URTI (in the care-giver) is passed to the child
causing damage to the respiratory tract, which increases the
chance of acquiring pneumococcus. It has been shown that the
inﬂammatory milieu increases susceptibility to pneumococcal
infection.38
The point prevalence of 81% for pneumococcal carriage in
children with HIV in Muheza is one of the highest rates recorded to
date. This high rate is partly a reﬂection of our comprehensive
approach to testing, using both culture and PCR. Children aged less
than 5 years had a carriage prevalence rate of 88%; in children aged
5–9 years, 77% were carriers and the rate among those aged 10–14
years was still high at 76%. Although the report by Hill et al.39 also
found a very high prevalence (80–90%), only infants younger than
18 months of age were studied. High rates have also been found in
other developing countries,40 but ours is the highest documented
for school-age children. Unfortunately, we do not have data on
carriage in HIV-negative children. It is important to note that the
high carriage rate is maintained in older children (5–14 years) who
have an HIV infection; carriage is normally inversely associated
with age.11,12 This underlines how much of a burden pneumococ-
cal carriage (and secondary disease) may be in older HIV-positive
children. It also suggests how important vaccination could be to
this population, especially given that about half of carriers had
serotypes covered by the 13-valent pneumococcal vaccine. It
should also be remembered that serotypes 1, 5, and 7 are covered
by the vaccine, but colonization was not demonstrated; these
serotypes are known to be rarely isolated from children’s
nasopharynges, but, by contrast, disease due to these serotypes
can be common. Thus, the vaccine may have more beneﬁts
(personal communication with Ben Amos).
Acquisition of some serotypes may be diminished by conjugate
vaccines as the vaccine can induce a strong antibody response.
Conjugate vaccines consist of capsular polysaccharides, chemically
linked with a highly immunogenic protein. They induce both B-
and T-cell responses, and can result in mucosal immunity to the
vaccine serotypes covered by the vaccine. However, it takes a
higher antibody concentration in the blood to prevent mucosal
colonization than to prevent invasive disease.17 This suggests that
the prevention of nasopharyngeal carriage can be used as a
surrogate for vaccine effectiveness, although it will give a more
conservative estimate.41 However, of concern, prevention of
carriage may lead to other serotypes (not in the vaccine) ﬁlling
the vacated ecological niche, i.e. colonizing and then potentially
causing replacement disease. The 13-valent conjugate pneumo-
coccal vaccine, were it 100% effective in preventing colonization,
could have prevented about half of the serotyped colonizing
episodes we detected. It is important to note that about 10% of all
pneumococcal isolates were BDL and also about 50% of the
typeable isolates are not covered by the 13-valent vaccine. For
these, other non-vaccine measures are required to prevent
acquisition of carriage.
In conclusion, we have identiﬁed novel risk factors that point to
possible opportunities for reducing carriage. There are few data on
carriage rates in children with HIV and fewer still in school-age
children with HIV. The rate of colonization observed in older
children of 76% is the highest we know of. Vaccination could help
prevent acquisition and thereby reduce invasive disease. Nowhere
L. Anthony et al. / International Journal of Infectious Diseases 16 (2012) e753–e757 e757is the need for fast efﬁcient roll out of the pneumococcal vaccine as
important as in HIV-positive populations like this one in Tanzania.
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